127 related articles for article (PubMed ID: 38460288)
1. Atezolizumab plus bevacizumab in advanced Merkel cell carcinoma: A prospective study.
de Sousa LG; Liu S; Bhosale P; Altan M; Darbonne W; Schulze K; Dervin S; Yun C; Mahvash A; Verma A; Futreal A; Gite S; Cuentas EP; Cho WC; Wistuba I; Yao JC; Woodman SE; Halperin DM; Ferrarotto R
Oral Oncol; 2024 Apr; 151():106747. PubMed ID: 38460288
[No Abstract] [Full Text] [Related]
2. Breaking avelumab resistance with combined ipilimumab and nivolumab in metastatic Merkel cell carcinoma?
Glutsch V; Kneitz H; Goebeler M; Gesierich A; Schilling B
Ann Oncol; 2019 Oct; 30(10):1667-1668. PubMed ID: 31350554
[No Abstract] [Full Text] [Related]
3. Current Role of Atezolizumab Plus Bevacizumab Therapy in the Sequential Treatment of Unresectable Hepatocellular Carcinoma.
Komatsu S; Yano Y; Fujishima Y; Ishida J; Kido M; Kuramitsu K; Yamamoto A; Goto T; Yanagimoto H; Toyama H; Ueda Y; Kodama Y; Fukumoto T
Anticancer Res; 2022 Mar; 42(3):1403-1412. PubMed ID: 35220233
[TBL] [Abstract][Full Text] [Related]
4. A Case of Pseudoprogression in Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab.
Watanabe Y; Ogawa M; Tamura Y; Suda S; Kaneko M; Kumagawa M; Hirayama M; Matsumoto N; Yamamoto T; Moriyama M
J Investig Med High Impact Case Rep; 2021; 9():23247096211058489. PubMed ID: 34845921
[TBL] [Abstract][Full Text] [Related]
5. Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial.
Galle PR; Finn RS; Qin S; Ikeda M; Zhu AX; Kim TY; Kudo M; Breder V; Merle P; Kaseb A; Li D; Mulla S; Verret W; Xu DZ; Hernandez S; Ding B; Liu J; Huang C; Lim HY; Cheng AL; Ducreux M
Lancet Oncol; 2021 Jul; 22(7):991-1001. PubMed ID: 34051880
[TBL] [Abstract][Full Text] [Related]
6. Atezolizumab plus Bevacizumab: A Novel Breakthrough in Hepatocellular Carcinoma.
Castet F; Willoughby CE; Haber PK; Llovet JM
Clin Cancer Res; 2021 Apr; 27(7):1827-1829. PubMed ID: 33472912
[TBL] [Abstract][Full Text] [Related]
7. Clinical significance of the discrepancy between radiological findings and biochemical responses in atezolizumab plus bevacizumab for hepatocellular carcinoma.
Iwamoto H; Shimose S; Niizeki T; Koga H; Torimura T
Clin Mol Hepatol; 2022 Jul; 28(3):575-579. PubMed ID: 35443321
[No Abstract] [Full Text] [Related]
8. Letter to the editor: Atezolizumab plus bevacizumab for hepatocellular carcinoma in the real world.
Zhang J; Fang J; Xun Z; Xu Y; Lu X; Zhao H
Hepatology; 2022 Oct; 76(4):E84-E85. PubMed ID: 35604038
[No Abstract] [Full Text] [Related]
9. Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib for Patients With Unresectable or Metastatic Hepatocellular Carcinoma.
Zhang X; Wang J; Shi J; Jia X; Dang S; Wang W
JAMA Netw Open; 2021 Apr; 4(4):e214846. PubMed ID: 33825837
[TBL] [Abstract][Full Text] [Related]
10. Checkpoint blockade for metastatic melanoma and Merkel cell carcinoma in HIV-positive patients.
Heppt MV; Schlaak M; Eigentler TK; Kähler KC; Kiecker F; Loquai C; Meier F; Tomsitz D; Brenner N; Niesert AC; Thonke R; Hauschild A; Berking C
Ann Oncol; 2017 Dec; 28(12):3104-3106. PubMed ID: 28950303
[No Abstract] [Full Text] [Related]
11. Portal hypertension, advanced hepatocellular carcinoma and therapy by atezolizumab-bevacizumab: A "menage à trois" !
Campion B; Larrey E; Wagner M; Rudler M; Thabut D; Allaire M
Clin Res Hepatol Gastroenterol; 2022 Feb; 46(2):101785. PubMed ID: 34384926
[No Abstract] [Full Text] [Related]
12. Is ageing a problematic hurdle to the efficacy of first-line atezolizumab plus bevacizumab in hepatocellular carcinoma?
An J; Shim JH
Liver Int; 2022 Nov; 42(11):2352-2353. PubMed ID: 36162086
[No Abstract] [Full Text] [Related]
13. Avelumab for the treatment of metastatic Merkel cell carcinoma.
Cordes LM; Gulley JL
Drugs Today (Barc); 2017 Jul; 53(7):377-383. PubMed ID: 28837181
[TBL] [Abstract][Full Text] [Related]
14. Significant response to atezolizumab plus bevacizumab treatment in unresectable hepatocellular carcinoma with major portal vein tumor thrombus: a case report.
Komatsu S; Fujishima Y; Kido M; Kuramitsu K; Goto T; Yanagimoto H; Toyama H; Fukumoto T
BMC Gastroenterol; 2021 Dec; 21(1):470. PubMed ID: 34911458
[TBL] [Abstract][Full Text] [Related]
15. Atezolizumab plus bevacizumab for advanced, unresectable hepatocellular carcinoma.
Tsilimigras DI; Moris D
J BUON; 2021; 26(2):637. PubMed ID: 34077021
[No Abstract] [Full Text] [Related]
16. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study.
Lee MS; Ryoo BY; Hsu CH; Numata K; Stein S; Verret W; Hack SP; Spahn J; Liu B; Abdullah H; Wang Y; He AR; Lee KH;
Lancet Oncol; 2020 Jun; 21(6):808-820. PubMed ID: 32502443
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of atezolizumab plus bevacizumab treatment for advanced hepatocellular carcinoma in the real world: a single-arm meta-analysis.
Gao X; Zhao R; Ma H; Zuo S
BMC Cancer; 2023 Jul; 23(1):635. PubMed ID: 37415136
[TBL] [Abstract][Full Text] [Related]
18. Advanced hepatocellular carcinoma with response to lenvatinib after atezolizumab plus bevacizumab.
Yano S; Kawaoka T; Johira Y; Miura R; Kosaka M; Shirane Y; Murakami S; Amioka K; Naruto K; Ando Y; Kosaka Y; Yamaoka K; Kodama K; Uchikawa S; Fujino H; Ohno A; Nakahara T; Murakami E; Okamoto W; Yamauchi M; Imamura M; Mori K; Arihiro K; Kuroda S; Kobayashi T; Ohdan H; Aikata H
Medicine (Baltimore); 2021 Oct; 100(42):e27576. PubMed ID: 34678902
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of atezolizumab plus bevacizumab combined with hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma.
Xin Y; Cao F; Yang H; Zhang X; Chen Y; Cao X; Zhou X; Li X; Zhou J
Front Immunol; 2022; 13():929141. PubMed ID: 35990634
[TBL] [Abstract][Full Text] [Related]
20. Liver dysfunction of Atezolizumab + Bevacizumab -a matter of life or death.
Obi S; Omata M
Liver Int; 2021 Jul; 41(7):1702-1703. PubMed ID: 34049421
[No Abstract] [Full Text] [Related]
[Next] [New Search]
